latest update:
[TrialBase DB]

trial summary · NCT06664814

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

Trial record from the TrialBase DB dataset, status RECRUITING, condition Focal Segmental Glomerulosclerosis, sponsored by National Human Genome Research Institute (NHGRI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06664814phase PHASE2enrollment 30start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN). In these conditions, specialized kidney cells called podocytes, which help prevent protein from leaking into the urine, are damaged. This can result in high levels of protein in the urine and, over time, worsening kidney function. In some people, the disease may progress to kidney failure requiring dialysis or a kidney transplant. Several treatments are currently available and can be beneficial, but they may cause significant side effects and may not work well for everyone. Therefore, there is a need for safer and more effective treatments for people with these types of kidney conditions. Objective: To test a study drug (ManNAc) in people with a podocyte disease, that includes Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Eligibility: People aged 18 years and older with a podocyte disease, that includes Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Design: Participants will have 5 to 6 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights. ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse …

Source record: https://clinicaltrials.gov/study/NCT06664814

Facts

registry idNCT06664814
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionFocal Segmental Glomerulosclerosis
sponsorNational Human Genome Research Institute (NHGRI)
sponsor classNIH
enrollment30
start date2026-10-27
primary completion2030-11-11
completion2030-12-01
results postednot reported

Conditions

  • Focal Segmental Glomerulosclerosis
  • Minimal Change Disease
  • Membranous Nephropathy

Interventions

  • ManNAc

Countries

  • United States

Intervention types: DRUG

Work with this record